Project: Low frequent HIV drug resistant polymorphisms in infants born to HIV sero-positive mothers: Implications on response to therapy

Acronym HIVDR (Reference Number: TMA2015SF-1037)
Duration 01/09/2017 - 31/08/2022
Project Topic In the present era where the major focus is on eliminating mother to child transmission of HIV, so much has been done to attain the now evidenced results. This has been more pronounced in the developed world where access to care and availability of resources have driven the mother to child transmission rates of HIV to levels as low as <1%. In the developing world however, lack of accessibility to care plus, lack of resources is causing these rates to lag behind. It is undeniable that even in the developing countries efforts have been made but there is still a lot that needs to be done. In this project, we propose to focus on one of the most vulnerable groups: HIV sero-positive infants born to HIV sero-positive mothers. With the elimination of mother to child transmission of HIV program, it is crucial that the infants who sero-convert get the best care to enable them live a productive life. In the low resource settings, these infants are initiated on a regimen without prior assessment of presence of drug resistance mutations. We propose to use cutting edge technology (Next generation sequencing) to determine the prevalence of drug resistance mutations (even at the lowest level) in these infants and also follow up these infants to see what impact these low level mutations have on response to therapy (in a longitudinal three year study using dry blood spot samples). Findings from this study will pave way for future recommendations in the standard of care guidelines at the national level as well as at the World Health Organization and this will ultimately improve quality of care in this very vulnerable population.
Network EDCTP2
Call Training and Mobility Awards: Senior Fellowships

Project partner

Number Name Role Country
1 Joint Clinical Research Center Limited Coordinator Uganda